Midostaurin®

Active substance

Midostaurin (PKC412) soft gelatin capsules of 25 mg

Holder

Novartis Pharma

Status

Running

Indication

Treatment of adult, newly diagnosed FLT3 mutated acute myeloid leukemia patients eligible for standard induction and consolidation chemotherapy.

Public documents

Approbation

Information for the patient

Informed consent

Last update

30/06/2016

Last updated on 13/02/2024